<?xml version="1.0" encoding="UTF-8"?>
<p>The explosive spread of Zika virus (ZIKV) during the 2015–2016 epidemics in Latin America attracted worldwide attention to this previously neglected disease. The lack of effective vaccines or small molecules to prevent or treat this infection remains a cause for concern and emphasizes the urgent need for new therapeutic options [
 <xref rid="B1-viruses-11-00365" ref-type="bibr">1</xref>]. ZIKV, an emerging flavivirus infection, causes several serious neurodevelopmental anomalies in the fetus, including microcephaly, congenital ZIKV syndrome (CZS), and even fetal demise [
 <xref rid="B2-viruses-11-00365" ref-type="bibr">2</xref>]. While most cases of ZIKV infection are asymptomatic, reports of rash, conjunctivitis, pain in the muscles or joints, and fever have been recorded in clinical manifestations of the disease, and in rare cases, ZIKV infection has been linked to the neuroinflammatory Guillain-Barré syndrome [
 <xref rid="B2-viruses-11-00365" ref-type="bibr">2</xref>].
</p>
